Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 1998, p. 1323-1328, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Phenotypic Study of Resistance of
-Lactamase-Inhibitor-Resistant TEM Enzymes Which Differ by Naturally
Occurring Variations and by Site-Directed Substitution at
Asp276
M. Manuela
Caniça,1,2,3,
Nathalie
Caroff,1,
Michel
Barthélémy,2
Roger
Labia,4
Rajagopal
Krishnamoorthy,3
Gérard
Paul,1,* and
Jean-Marie
Dupret3
Laboratoire de Recherche en Microbiologie,
UFR Cochin-Port-Royal, 75014 Paris,1
Muséum National d'Histoire Naturelle, CNRS URA 401,
75231 Paris,2
UMR 175, 29000 Quimper,4 and
INSERM U 458,
Hôpital Robert Debré, 75019 Paris,3
France
Received 31 July 1997/Returned for modification 26 November
1997/Accepted 23 March 1998
 |
ABSTRACT |
At this time an amino acid substitution at position 276 in the
TEM-1 enzyme is associated with an additional substitution at position
69 in natural
-lactamase-inhibitor-resistant (IRT)
-lactamases.
The effect of the Asn276
Asp substitution on resistance
was assessed with the Asn276Asp variant, generated by site-directed
mutagenesis. The mutant was resistant to
-lactamase inhibitors, but
the MICs of amoxicillin combined with clavulanic acid or tazobactam
were strikingly different for E. coli strains producing the
Asn276Asp variant and those producing naturally occurring IRTs with
single or double substitutions. The inhibitory effects of clavulanic
acid and tazobactam were the same in IRTs with substitutions at
position 69 (IRT-5 and IRT-6). The effect of clavulanic acid on the
MICs of amoxicillin for the Asn276Asp variant was greater than that
of tazobactam. In IRTs with double substitutions, at positions
69 plus 276 (IRT-4, IRT-7, and IRT-8) or 69 plus 275 (IRT-14),
tazobactam was a more potent inhibitor than clavulanic acid. The effect
of the Asn276
Asp substitution on the values of the
kinetic constants and the concentration required to inhibit by 50% the
hydrolysis of benzylpenicillin confirms that this single mutation is
responsible for resistance to
-lactamase inhibitors. Molecular
modeling of the Asn276Asp mutant shows that Asp276 can form
two salt bonds with Arg244 close to the penicillin-binding
cavity. The addition of the Asp276 mutation to that
preexisting at position 69 confers a higher selective advantage to
bacteria, as shown by the reduction in
-lactamase inhibitor
efficiencies of the double variants. Therefore, the emergence of
multiple mutations in TEM
-lactamases by virtue of the use of
-lactamase inhibitors increases selection pressure resulting in the
convergent evolution of resistant strains.
 |
INTRODUCTION |
The
-lactam antibiotics are the
most frequently prescribed antimicrobial agents in clinical practice.
The enzymes of the
-lactamase family of gram-negative bacteria play
a significant role in the development of resistance to
-lactam
antibiotics. The frequent occurrence of
-lactamase genes in readily
transmissible plasmids and their possible integration into bacterial
chromosomes is of concern in the management of antimicrobial therapy in
the community and in hospital centers. The evolution of
extended-spectrum resistance is mediated by mutant derivatives of the
TEM and SHV
-lactamases (17).
Strains resistant to inhibitors of
-lactamases and containing
TEM-derived
-lactamases have been described (2, 3, 5, 7, 12,
19, 39, 42). These
-lactamase-inhibitor-resistant (IRT) TEM
-lactamases are encoded by blaIRT genes
that carry mutations affecting the kinetic properties of the enzymes by
altering the binding of both the
-lactams and the
-lactamase
inhibitors (24). The structure-function relationships of
some of these mutations have been investigated with variants generated
in vitro (3, 16, 21, 29, 38). The effect of the sequence
variation at position 276 of the TEM-1
-lactamase
(Asn276
Asp) has been examined by this approach
(38) to assess enzyme kinetics and the resistance pattern in
qualitative terms. This substitution has never occurred alone in
natural variants and is always accompanied by substitution of the
methionine at position 69 (Met69) in
-lactamase.
We studied the quantitative effects of the IRT variants with single and
double substitutions on resistance to antibiotic-inhibitor combinations. We generated an Asn276
Asp variant
(hereafter designated Asn276Asp) by site-directed mutagenesis. We
compared its phenotypic characteristics with those of various naturally
occurring IRTs (IRT-5, IRT-6, IRT-7, and IRT-8 and the reference IRTs
IRT-4 [7] and IRT-14 [10]) and the in
vitro-generated variants M69L (16) and W165R
(33).
(This work was presented in part at the 16th Interdisciplinary Meeting
on Anti-Infectious Chemotherapy, Paris, France, 1996 [11].)
 |
MATERIALS AND METHODS |
Bacterial strains, plasmids, and phage.
The characteristics
of the bacterial strains, plasmids, and phage used in this study are
given in Table 1. The phagemid
pBluescript-II KS(
) (Stratagene Cloning Systems, La Jolla, Calif.),
which encodes the TEM-1
-lactamase, was used for site-directed
mutagenesis. This phagemid was propagated in Escherichia
coli RZ1032 to obtain the single-stranded template DNA for
site-directed mutagenesis. Mutated DNA (pMBS276D) was introduced into
the bacterial host E. coli XL-1 Blue, which was then tested
for antibiotic susceptibility. The E. coli strains producing
IRT-5 (P30), IRT-6 (P9), IRT-7 (P11), IRT-8 (P12), IRT-4
(7), and IRT-14 (10) and the control strain expressing the TEM-1 (R111)
-lactamase were used for MIC assays.
Media and chemicals.
The bacteria used for site-directed
mutagenesis were cultured in Luria-Bertani (Gibco BRL, Life
Technologies, Paisley, Scotland) and 2× YT media (36).
Brain heart infusion (Difco Laboratories, Detroit, Mich.) medium was
used to culture bacteria for
-lactamase production. Mueller-Hinton
agar (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France) was used
for the MIC assay. The
-lactams used in this study for determination
of the MICs and the values of the kinetic constants were those used in
previous work (10).
Plasmid purification and bacterial transformation.
Plasmid
DNA was isolated from E. coli by the alkaline lysis method
(36). Competent E. coli cells (XL-1 Blue and
RZ1032) were prepared and transformed with plasmid DNA by the calcium chloride method (15). Attempts to transfer the clinical
plasmids encoding the blaIRT-5,
blaIRT-6,
blaIRT-7, and
blaIRT-8 genes to E. coli were
unsuccessful.
Single-stranded DNA preparation and site-directed mutagenesis of
the TEM-1
-lactamase.
We used the numbering of amino acid
residues in the
-lactamase sequence proposed by Ambler et al.
(1). Single-stranded plasmid DNA was prepared as described
previously (36). Site-directed mutagenesis was carried out
as described by Kunkel et al. (25) with an
oligodeoxyribonucleotide with the intended substitution (underlined):
5'-ATG AAC GAG ATA GAC AGA T-3'. E. coli XL-1
Blue colonies containing the plasmid DNA with the mutant
bla gene were selected for ampicillin and tetracycline
resistance (Apr and Tcr, respectively).
Identification and characterization of mutants.
Plasmids
were isolated from resistant clones and were tested for the presence of
the intended mutation with a diagnostic Tsp509I enzyme as
described previously (13). Plasmids testing positive were further sequenced (37) to confirm the presence of the
expected mutation in the plasmid DNA (pMBS276D).
MIC assays and purification and IEF of
-lactamases.
Bacterial susceptibility to
-lactams was measured by the agar
dilution test as described previously (10).
Independent E. coli XL-1 Blue clones carrying pMBS276D
or TEM-1 were grown overnight at 37°C in a large volume (3 to 5 liters) of brain heart infusion medium with continuous shaking.
The preparation of cell-free lysates, enzyme purification (7,
40), reverse-phase high-performance liquid chromatography
(34), analytical isoelectric focusing (IEF)
(31), and
-lactamase detection (27) were
carried out by published procedures. The enzymes used as controls in
IEF were TEM-1 (R111) (27), TEM-2 (RP4) (32),
IRT-1 (TEM-31), and IRT-2 (TEM-30) (40).
Kinetic parameter value determinations.
The values of
Km, Ki and
Vmax and the concentration required to inhibit
by 50% the hydrolysis of benzylpenicillin (IC50) of the
Asn276Asp
-lactamase were estimated at 37°C by computerized microacidimetry at pH 7.0 (26). The values of the kinetic
parameters (Vmax and Km)
were derived by weighted linear regression of these data. If the
Vmax and Km values were
very low they were simply not reported or Ki was
measured by competitive inhibition with a reporter substrate,
benzylpenicillin (1,000 µM), instead (9, 28). Purified
-lactamases were used for the kcat assay. The quantitative effect of inhibitors on the activities of the wild-type or
mutant
-lactamases was assessed by determining the IC50.
Five concentrations of inhibitors were used: from 10 to 300 µM for TEM-1 or 100 to 1,000 µM for the mutant (clavulanic acid), from 0.5 to 100 µM for TEM-1 or for the mutant (sulbactam), from 25 to 500 µM for TEM-1 or for the mutant (tazobactam), and from 2.5 to 10 µM
for TEM-1 or for the mutant (brobactam). The
-lactamase was
preincubated with the inhibitor for 10 min at 37°C in saline buffer
at pH 7.0, and the assay was initiated by the addition of 1 mM
benzylpenicillin. Inhibition data for clavulanic acid were plotted
against the inhibitor: enzyme ratio to determine the partition ratio
for inactivation from the extrapolated value for 100% inactivation.
One unit of
-lactamase is the amount of enzyme that hydrolyzes 1 µmol of benzylpenicillin per min at 37°C under these experimental
conditions.
Molecular modeling.
The crystal structure of the PC1
-lactamase is available from the Protein Data Bank, Brookhaven
National Laboratory, Brookhaven, Conn., under the entry 3BLM
(20), as the structure of TEM-1
-lactamase (1XPB)
(18) and a closely related TEM-1
-lactamase (1BTL)
(23). Molecular modeling of the Asp276 TEM
mutant was performed by using the Amber force field (41).
 |
RESULTS |
Isoelectric point.
The mutant
-lactamase encoded
by pMBS276D was shown to have a pl of 5.2 by analytical IEF.
Susceptibility to
-lactams of E. coli producing
Asn276Asp
-lactamase.
The MICs for E. coli Asn276Asp
are presented in Table 2. For E. coli XL-1 Blue carrying pMBS276D, the MICs of amoxicillin were
eightfold higher and those of ticarcillin and piperacillin fourfold
higher than those for the wild-type in the presence of clavulanate.
Tazobactam did not reduce the MICs of these
-lactams. Intriguingly,
we found a striking difference in the MICs for the TEM-1 encoded by
R111 and that encoded by pBSKS in the presence of tazobactam. Both
plasmids were thought to encode the wild-type TEM-1 enzyme. The MICs of
mecillinam, imipenem, and cephalosporins for the wild-type TEM-1
(pBSKS) and the Asn276Asp variant were similar.
Effect of inhibitor-amoxicillin combination on IRTs characterized
by one or two amino acid substitutions.
In the presence of
-lactamase inhibitors, the MICs of amoxicillin were fourfold lower
for strains producing IRT-5 and eightfold lower for strains producing
IRT-6. The effects of clavulanic acid and tazobactam on these single
variants were the same (Fig. 1). The MICs
of amoxicillin with clavulanic acid for the double variant IRT-7- and
IRT-8-producing strains were reduced by half. In the presence of
tazobactam, they were 16-fold lower for strains producing IRT-7 and
4-fold lower for strains producing IRT-8.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 1.
MICs for E. coli producing TEM-1 wild-type
enzymes, TEM-1 variant enzymes obtained by site-directed mutagenesis,
and natural IRT enzymes. The effects of clavulanate and tazobactam
combined with amoxicillin were determined. The following enzymes were
used: wild-type TEM-1 enzymes R111 (this study), pBSKS (this study),
and pBR322 (33); TEM-1 variants pMBS276D with Asn276Asp
(this study) and pBR322 with Trp165Arg (33); natural IRT
enzymes (this study) P30 producing IRT-5 (Met69Leu), P9 producing IRT-6
(Met69Val), P11 producing IRT-7 (Met69Val plus Asn276Asp), and P12
producing IRT-8 (Met69Ile plus Asn276Asp); and Pey producing IRT-4
(Met69Leu plus Asn276Asp) (7) and P37 producing IRT-14
(Met69Leu plus Arg275Gln) (10).
, amoxicillin;
, amoxicillin plus clavulanate;
, amoxicillin plus tazobactam.
|
|
Effects of the Asn276
Asp substitution in TEM-1
-lactamase on kinetic parameters.
The
-lactamase mutant
Asn276Asp and the wild-type TEM-1
-lactamase
(Asn276) were produced in E. coli with a
high-level expression vector. They were extracted from E. coli and purified. The specific activities were 5,300 U/mg for the
mutant and 2,400 U/mg for TEM-1. The kinetic parameters for the
Asn276Asp and TEM-1
-lactamases were determined for 17
-lactams
and are summarized in Tables 3 and
4. The chief results were as follows
described below.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Kinetic parameters for the hydrolysis of -lactam
substrates by the wild-type (pBSKS/TEM-1) and mutant
(Asp276) -lactamasesa
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Ratio of
kcat/Km of mutant enzymes
with Asp276 and Leu69 substitutions and of
IRT-4 and IRT-14 -lactamases relative to that of the
wild-type (pBSKS/TEM-1)a
|
|
(i) Penicillins. The Asn276Asp enzyme hydrolyzed all
penicillins tested except oxacillin. The
kcat
values of the mutant
enzyme were 1.5- to 2-fold higher than those
of TEM-1. The
Km values of the mutant enzyme
were four- to ninefold higher than
those of the wild-type enzyme.
Mecillinam was a poor substrate.
Consequently, the
kcat/
Km values of the
mutant enzyme for penicillins
were reduced two- to sixfold.
(ii) Cephalosporins. The
kcat and
Km values of the enzyme were unaffected except
for those for cephaloridine, for which
the
kcat/
Km value of the
mutant was three-fold higher than that
of the wild type. Aztreonam,
expanded-spectrum cephalosporins,
and cefoxitin were not substrates for
these

-lactamases. The
catalytic efficiencies
(
kcat/
Km) of the
Asn276Asp

-lactamase
for penicillins were less than 50% of those of
the TEM-1 enzyme
(Table
4). The catalytic efficiencies of the Asn276Asp

-lactamase
for mecillinam and cephalosporins were comparable to or
higher
than those of TEM-1. The IC
50s for TEM-1 and the
mutant

-lactamases
are given in Table
5. Clavulanic acid was 100 times more
active
than sulbactam against the mutant enzyme, 2.5 times more active
than tazobactam, and 4 times less active than brobactam. The
IC
50s
for the mutant were sevenfold higher with clavulanic
acid, twofold
higher with tazobactam, and similar to those for TEM-1
with sulbactam
and brobactam. The inactivation of the mutant was
progressive,
with partition ratio of 950 for inactivation by clavulanic
acid,
compared to a ratio of 120 for the TEM-1

-lactamase.
Molecular modeling.
Figure 2, based on the
crystal structure of TEM-1
-lactamase (18, 23), shows the
stereo view of the environment of Asp276 and
interactions with Arg244 of the Asn276Asp mutant,
in which two salt bonds can be formed between those amino acids.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Molecular modeling of the Asn276Asp mutant of TEM-1:
stereo view of the environment of Asp276 and interactions
with Arg244. Hydrogen bonds are indicated by dashed lines.
The backbones of -helices h1, h2, and h10 are shown (at the bottom)
as thin lines.
|
|
 |
DISCUSSION |
Previous work has stressed the importance of the
Asn276
Asp change in
-lactamase for conferring
resistance to clavulanic acid (38). This change also
decreases the substrate affinity and catalytic efficiency of
-lactamase. However, this substitution has never been found alone in
strains with naturally occurring IRT and is always accompanied by
another substitution, at position 69, which contributes on its own to
the IRT phenotype. Thus, site-directed mutagenesis at position 276 was
used to investigate the role of this position in inhibitor-resistant
phenotypes. The previous study evaluated only the qualitative effects
of antibiotic-inhibitor combinations.
In this study we investigated the effects of the
Asn276
Asp substitution, generated by
site-directed mutagenesis of the
blaTEM-1 gene (the variant was
Asn276Asp), on other functional characteristics of TEM-1
-lactamase
and, in particular, on the MICs and IC50s. We also compared
the properties of this enzyme with those of naturally occurring
variants to assess the contribution of the amino acid change to the
resistance phenotype.
The observed differences in susceptibility to clavulanate and
tazobactam of E. coli bearing pBSKS and E. coli
bearing R111 (Table 1) are probably due to the higher copy number of
pBSKS, as observed previously for E. coli resistant to
-lactamase inhibitors (30). However, the Asn276Asp
variant was more resistant than the wild type TEM-1 to clavulanate and
tazobactam (Table 2). Interestingly, this enhanced resistance to
-lactamase inhibitors has already been observed by determination of
the MICs for the Asn276
Gly variant of OHIO-1
(4). This substitution did not affect the level of
resistance to penicillins and cephalosporins according to the observed
MICs (Table 2). Clavulanate and tazobactam had different effects on
naturally occurring IRT enzymes, depending on whether the strains had a
single substitution (at position 69) or double substitutions (at both
position 69 and position 275 or 276) in their
-lactamases (Fig. 1).
Indeed, clavulanic acid was more potent against strains producing IRT
enzymes with single substitutions than against those with double
substitutions. Tazobactam was more potent than clavulanic acid
against strains producing IRT enzymes with double substitutions. The
double substitution (positions 69 and 276) was also present in IRT-10
along with a third substitution at position 165 (19), which
was itself responsible for an IRT phenotype (W165R) (33)
(Fig. 1). These observations might be in agreement with the mechanisms,
proposed by Imtiaz et al. (22), that differentiate
inhibition by clavulanic acid from that by tazobactam.
Some changes in the functional properties of the enzyme caused by the
Asp276 mutation may not be apparent, because determination
of the MIC takes into account the whole response of bacteria.
However, kinetic results were consistent with the MICs for the
mutant enzyme. Higher Km and
kcat values were recorded in these studies. This
demonstrated the close relationship between enzyme properties and
resistance to
-lactams. We also found that the Asn276Asp mutant
enzyme had lower catalytic efficiencies
(kcat/Km) than TEM-1 due
to the higher Km values for penicillins (Table
3), suggesting that the substrates may interact less efficiently with
the mutant enzyme. Our kinetic data were consistent with those
previously reported for the same mutation in a different plasmid
construct and host bacterium (38). Single substitutions at
positions 69 (mutant M69L) (16) and 276 (mutant Asn276Asp)
independently caused similar reductions in the catalytic efficiency of
TEM-1. There was a greater reduction in catalytic efficiency when
mutations at both positions occurred together, as in mutant IRT-4
(7). There was a similar reduction in catalytic
efficiency with the doubly substituted IRT-14 mutant, demonstrating the importance of the mutation at position 275 in conferring the IRT phenotype (10) (Table 4).
In the evolutionary process of IRTs, the amino acid substitution of the
methionine at position 69 with leucine, valine, or isoleucine appears
to be crucial in the first stages of the emergence of IRTs
(12). The addition of the Asp276 mutation to the
preexisting mutation at position 69 should confer a higher
selective advantage to the bacterium. Similar selection processes
probably operate for the mutation at position 275 (Arg275
Gln) (a similar reduction in catalytic
efficiency for IRT-14; Table 4), for which no site-directed mutagenesis
or a functional assay has so far been done. The
Trp165
Arg substitution, which accounts for
resistance to inhibitors (29, 33), would further contribute
to such a selection process. This substitution occurs with the two
other substitutions (positions 69 and 276) in the naturally occurring
IRT-10 (19). Thus, the strain producing the IRT-10
-lactamase may have undergone stronger selection pressure than the
others.
The possible mechanism of the resistance generated by the substitutions
at positions 275 and 276 is discussed below. These amino acid positions
are not located close to the conserved boxes in class A enzymes. In
TEM-1, they are at the beginning of helix h11 (23). In the
crystal structure of PC1
-lactamase (20), as the
structures of TEM-1
-lactamase (18) and a closely related TEM-1
-lactamase (23) show, Arg244 is located
on
sheet s-4 and its guanidinium side chain is close to the
penicillin-binding cavity. In PC1, Asp276 forms a
salt bond with Arg244, whereas in TEM-1,
Asn276 forms hydrogen bonds with the guanidinium of
Arg244. Molecular modeling of the Asp276 TEM
mutant suggests that the Asp276 residue of the mutant forms
a salt bond, as shown in Fig. 2, very similar to that observed with the
PC1 enzyme. Nevertheless, the PC1
-lactamase is susceptible to
clavulanic acid. In fact, the interactions of clavulanic acid with the
PC1 and TEM
-lactamases are not the same. With the PC1 enzyme,
clavulanic acid forms a stable acyl enzyme, a
cis-enamine susceptible to rearrangement into a
decarboxylated trans-enamine (14). In the case of
TEM enzymes, as shown with the TEM-2 enzyme, the acyl enzyme is not stable and acylation of Ser70 is followed by cross-linking of the
enzyme with serine 130, as observed by electrospray ionization mass
spectroscopy (6). Thus, in IRTs, it is credible that the formation of the acyl enzyme is still possible. This is shown in
kinetic experiments with a transient inhibition, but the acyl enzyme
almost totally reactivates because the level of cross-linking seems
very low.
Therefore, IRT enzymes with double substitutions are the result of
convergent evolution, because each substitution itself causes the
overall resistance phenotype. There are differences in the behaviors of
IRT enzymes with single and double substitutions toward different
inhibitors. This highlights the importance of considering such enzyme
sequence variations in strategies to design new inhibitor molecules.
 |
ACKNOWLEDGMENTS |
We thank SmithKline Beecham for providing clavulanic acid,
Lederle for providing tazobactam, and Pfizer for providing sulbactam. We are grateful to C. Deloménie for the gift of the RZ1032 and XL-1 Blue strains and for helpful discussions about the site-directed mutagenesis method. We thank L. Gilly for performing purification of
the
-lactamases.
This work was supported in part by a BQR from Conseil Scientifique UFR
Médecine Cochin and a grant from the Institut National de la
Santé et de la Recherche Médicale (INSERM). During this study, M.M.C. was supported first by the European Human Capital and
Mobility Program and later by PRAXIS XXI research fellowships provided
by Junta Nacional de Investigação Cientifica e
Tecnológica, Lisbon, Portugal.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Recherche en Microbiologie, UFR de Medecine Cochin-Port-Royal, 24, rue du Faubourg Saint-Jacques, 75014 Paris, France. Phone:
(33)(01)44.41.23.43. Fax: (33)(01)44.41.23.42. E-mail:
paul{at}citi2.fr.
Present address: Department of Medical Biology, National Institute
of Health Dr. Ricardo Jorge, 1699 Lisboa Codex, Portugal.
Present address: Laboratoire de Bacrériologie, CHU Nantes,
44035 Nantes Cédex 01 France.
 |
REFERENCES |
| 1.
|
Ambler, R. P.,
A. F. W. Coulson,
J.-M. Frère,
J.-M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-272.
|
| 2.
|
Belaaouaj, A.,
C. Lapoumeroulie,
M. M. Caniça,
G. Vedel,
P. Névot,
R. Krishnamoorthy, and G. Paul.
1994.
Nucleotide sequences of the genes coding for the TEM-like -lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2).
FEMS Microbiol. Lett.
120:75-80[Medline].
|
| 3.
|
Blazquez, J.,
M.-R. Baquero,
R. Canton,
I. Alos, and F. Baquero.
1993.
Characterization of a new TEM-type -lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Antimicrob. Agents Chemother.
37:2059-2063[Abstract/Free Full Text].
|
| 4.
|
Bonomo, R. A.,
C. G. Dawes,
J. R. Knox, and D. M. Shlaes.
1995.
-Lactamase mutations far from the active site influence inhibitor binding.
Biochim. Biophys. Acta
1247:121-125[Medline].
|
| 5.
|
Bret, L.,
C. Chanal,
D. Sirot,
R. Labia, and J. Sirot.
1996.
Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 -lactamase produced by Proteus mirabilis strains.
J. Antimicrob. Chemother.
38:183-191[Abstract/Free Full Text].
|
| 6.
|
Brown, R. P. A.,
R. T. Aplin, and C. J. Schofield.
1996.
Inhibition of TEM-2 -lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
Biochemistry
35:12421-12432[Medline].
|
| 7.
|
Brun, T.,
J. Péduzzi,
M. M. Caniça,
G. Paul,
P. Névot,
M. Barthélémy, and R. Labia.
1994.
Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to -lactamase inhibitors.
FEMS Microbiol. Lett.
120:111-118[Medline].
|
| 8.
|
Bullock, W. O.,
J. M. Fernandez, and J. M. Short.
1987.
XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection.
Bio Techniques
5:376-378.
|
| 9.
|
Bush, K., and R. B. Sykes.
1986.
Methodology for the study of -lactamases.
Antimicrob. Agents Chemother.
30:6-10[Free Full Text].
|
| 10.
|
Caniça, M. M.,
M. Barthélémy,
L. Gilly,
R. Labia,
R. Krishnamoorthy, and G. Paul.
1997.
Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type -lactamases.
Antimicrob. Agents Chemother.
41:374-378[Abstract].
|
| 11.
|
Caniça, M. M.,
C. Deloménie,
R. Labia,
R. Krishnamoorthy, and G. Paul.
1996.
Characterization of the mutant produced by site-directed mutagenesis generating the substitution Asn-276 Asp in the critical proximity of Arg-244 in TEM-1 -lactamase, abstr. 24/C3, p. 100.
In
Program and abstracts of the 16th Interdisciplinary Meeting on Anti-Infectious Chemotherapy.
|
| 12.
|
Caniça, M. M. M.,
C. Y. Lu,
R. Krishnamoorthy, and G. C. Paul.
1997.
Molecular diversity and evolution of blaTEM genes encoding -lactamases resistant to clavulanic acid in clinical E. coli.
J. Mol. Evol.
44:57-65[Medline].
|
| 13.
|
Caroff, N.,
M. M. M. Caniça,
L. Gilly,
R. Krishnamoorthy, and G. Paul.
1995.
Detection of a ponctual mutation in the blaTEM gene using an artificially created restriction site, abstr. 360/P24, p. 228.
In
Program and abstracts of the 15th Interdisciplinary Meeting on Anti-Infectious Chemotherapy.
|
| 14.
|
Chen, C. C. H., and O. Herzberg.
1992.
Inhibition of -lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies.
J. Mol. Biol.
224:1103-1113[Medline].
|
| 15.
|
Cohen, S. N.,
A. C. Y. Chang, and L. Hsu.
1972.
Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA.
Proc. Natl. Acad. Sci. USA
69:2110-2114[Abstract/Free Full Text].
|
| 16.
|
Delaire, M.,
R. Labia,
J.-P. Samama, and J.-M. Masson.
1992.
Site-directed mutagenesis at the active site of Escherichia coli TEM-1 -lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis.
J. Biol. Chem.
267:20600-20606[Abstract/Free Full Text].
|
| 17.
|
Du Bois, S. K.,
M. S. Marriott, and S. G. B. Amyes.
1995.
TEM- and SHV-derived extended-spectrum -lactamases: relationship between selection, structure and function.
J. Antimicrob. Chemother.
35:7-22[Abstract/Free Full Text].
|
| 18.
|
Fonzé, E.,
P. Charlier,
Y. Toth,
M. Vermeire,
X. Raquet,
A. Dubus, and J.-M. Frère.
1995.
TEM-1 -lactamase structure solved by molecular replacement and refined structure of the S235A mutant.
Acta Crystallogr.
51:682-694.
|
| 19.
|
Henquell, C.,
C. Chanal,
D. Sirot,
R. Labia, and J. Sirot.
1995.
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM -lactamases from clinical isolates of Escherichia coli.
Antimicrob. Agents Chemother.
39:427-430[Abstract/Free Full Text].
|
| 20.
|
Herzberg, O.
1991.
Refined crystal structure of -lactamase from Staphylococcus aureus PC1 at 2.0 Å resolution.
J. Mol. Biol.
217:701-719[Medline].
|
| 21.
|
Imtiaz, U.,
E. Billings,
J. R. Knox,
E. K. Manavathu,
S. A. Lerner, and S. Mobashery.
1993.
Inactivation of class A -lactamases by clavulanic acid: the role of arginine-244 in a proposed nonconcerted sequence of events.
J. Am. Chem. Soc.
115:4435-4442.
|
| 22.
|
Imtiaz, U.,
E. M. Billings,
J. R. Knox, and S. Mobashery.
1994.
A structure-based analysis of the inhibition of class A -lactamases by sulbactam.
Biochemistry
33:5728-5738[Medline].
|
| 23.
|
Jelsch, C.,
L. Mourey,
J.-M. Masson, and J.-P. Samama.
1993.
Crystal structure of Escherichia coli TEM-1 -lactamase at 1.8 Å resolution.
Proteins Struct. Funct. Genet.
16:364-383.
[Medline] |
| 24.
|
Knox, J. R.
1995.
Extended-spectrum and inhibitor-resistant TEM-type -lactamases: mutations, specificity, and three-dimensional structure.
Antimicrob. Agents Chemother.
39:2593-2601[Medline].
|
| 25.
|
Kunkel, T. A.,
J. D. Roberts, and R. A. Zakour.
1987.
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Methods Enzymol.
154:367-382[Medline].
|
| 26.
|
Labia, R.,
J. Andrillon, and F. Le Goffic.
1973.
Computerized microacidimetric determination of -lactamase Michaelis-Menten constants.
FEBS Lett.
33:42-44[Medline].
|
| 27.
|
Labia, R.,
M. Barthélémy,
C. Fabre,
M. Guionie, and J. Péduzzi.
1979.
Kinetic studies of three R-factor mediated -lactamases, p. 429-442.
In
J. M. T. Hamilton-Miller, and J. T. Smith (ed.), Beta-lactamases. Academic Press, London, United Kingdom.
|
| 28.
|
Labia, R.,
V. Lelievre, and J. Peduzzi.
1980.
Inhibition kinetics of three R-factor-mediated -lactamases by a new -lactam sulfone (CP 45899).
Biochim. Biophys. Acta
611:351-357[Medline].
|
| 29.
|
Lenfant, F.,
A. Petit,
R. Labia,
L. Maveyraud,
J.-P. Samana, and J.-M. Masson.
1993.
Site-directed mutagenesis of -lactamase TEM-1. Investigating the potential role of specific residues on the activity of Pseudomonas-specific enzymes.
Eur. J. Biochem.
217:939-946[Medline].
|
| 30.
|
Martinez, J. L.,
M. F. Vicente,
A. Delgado-Iribarren,
J. C. Perez-Diaz, and F. Baquero.
1989.
Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli.
Antimicrob. Agents Chemother.
33:595[Free Full Text]. (Letter.)
|
| 31.
|
Matthew, M.,
A. M. Harris,
M. J. Marshall, and G. W. Ross.
1975.
The use of analytical isoelectric focusing for detection and identification of -lactamases.
J. Gen. Microbiol.
88:169-178[Medline].
|
| 32.
|
Matthew, M., and R. W. Hedges.
1976.
Analytical isoelectric focusing of R factor-determined -lactamases: correlation with plasmid compatibility.
J. Bacteriol.
125:713-718[Abstract/Free Full Text].
|
| 33.
|
Petit, A.,
E. Jullian, and R. Labia.
1991.
Substitution du tryptophane-165 par une arginine dans la beta-lactamase TEM-1.
C. R. Acad. Sci. Paris
312:993-997.
|
| 34.
|
Reynaud, A.,
J. Péduzzi,
M. Barthélémy, and R. Labia.
1991.
Cefotaxime-hydrolysing activity of the -lactamase of Klebsiella oxytoca D488 could be related to a threonine residue at position 140.
FEMS Microbiol. Lett.
81:185-192.
|
| 35.
|
Russel, M.,
S. Kidd, and M. R. Kelley.
1986.
An improved filamentous helper phage for generating single-stranded plasmid DNA.
Gene
45:333-338[Medline].
|
| 36.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 38.
|
Saves, I.,
O. Burlet-Schiltz,
P. Swarén,
F. Lefèvre,
J.-M. Masson,
J.-C. Promé, and J.-P. Samama.
1995.
The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the -lactamase resistance to clavulanic acid.
J. Biol. Chem.
270:18240-18245[Abstract/Free Full Text].
|
| 39.
|
Stapleton, P.,
P.-J. Wu,
A. King,
K. Shannon,
G. French, and I. Phillips.
1995.
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
Antimicrob. Agents Chemother.
39:2478-2483[Abstract].
|
| 40.
|
Vedel, G.,
A. Belaaouaj,
L. Gilly,
R. Labia,
A. Philippon,
P. Névot, and G. Paul.
1992.
Clinical isolates of Escherichia coli producing TRI -lactamases: novel TEM-enzymes conferring resistance to -lactamase inhibitors.
J. Antimicrob. Chemother.
30:449-462[Abstract/Free Full Text].
|
| 41.
|
Weiner, S. J.,
P. A. Kollman,
D. A. Case,
U. C. Singh,
C. Ghio,
G. Alagona,
S. J. Profeta, and P. Weiner.
1984.
A new force field for molecular mechanical simulation of nucleic acids and proteins.
J. Am. Chem. Soc.
106:764-784.
|
| 42.
|
Zhou, X. Y.,
F. Bordon,
D. Sirot,
M.-D. Kitzis, and L. Gutmann.
1994.
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 -lactamase conferring resistance to -lactamase inhibitors.
Antimicrob. Agents Chemother.
38:1085-1089[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, June 1998, p. 1323-1328, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Stapleton, P. D., Shannon, K. P., French, G. L.
(1999). Construction and Characterization of Mutants of the TEM-1 beta -Lactamase Containing Amino Acid Substitutions Associated with both Extended-Spectrum Resistance and Resistance to beta -Lactamase Inhibitors. Antimicrob. Agents Chemother.
43: 1881-1887
[Abstract]
[Full Text]
-
Wu, S. W., Dornbusch, K., Kronvall, G.
(1999). Genetic Characterization of Resistance to Extended-Spectrum beta -Lactams in Klebsiella oxytoca Isolates Recovered from Patients with Septicemia at Hospitals in the Stockholm Area. Antimicrob. Agents Chemother.
43: 1294-1297
[Abstract]
[Full Text]